Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 22.80B | 23.63B | 20.71B | 20.35B | 19.04B | 16.97B |
Gross Profit | 7.44B | 8.01B | 6.68B | 6.27B | 6.27B | 5.56B |
EBITDA | 2.80B | 3.95B | 3.14B | 2.96B | 3.29B | 2.62B |
Net Income | 2.38B | 2.47B | 1.91B | 1.68B | 2.05B | 1.50B |
Balance Sheet | ||||||
Total Assets | 26.38B | 27.00B | 27.92B | 26.51B | 25.88B | 24.94B |
Cash, Cash Equivalents and Short-Term Investments | 5.49B | 7.92B | 6.54B | 5.93B | 5.54B | 5.32B |
Total Debt | 0.00 | 0.00 | 21.37M | 23.94M | 26.99M | 20.00M |
Total Liabilities | 4.93B | 5.10B | 4.81B | 4.61B | 4.39B | 4.41B |
Stockholders Equity | 21.44B | 21.90B | 23.11B | 21.90B | 21.49B | 20.53B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 3.20B | 1.13B | 538.07M | 1.55B | 1.84B |
Operating Cash Flow | 0.00 | 3.59B | 1.84B | 947.42M | 1.79B | 2.41B |
Investing Cash Flow | 0.00 | 182.80M | -281.44M | 716.59M | -604.65M | -1.46B |
Financing Cash Flow | 0.00 | -3.68B | -883.04M | -1.18B | -862.55M | -355.80M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $9.62T | 18.08 | 11.81% | 2.17% | 6.06% | 3.97% | |
76 Outperform | €586.70B | 13.75 | 18.55% | 4.83% | 10.88% | 14.80% | |
75 Outperform | $224.71B | 9.61 | 9.01% | 3.20% | 0.32% | 31.76% | |
74 Outperform | ¥689.88B | 11.90 | 7.04% | 4.61% | 5.74% | 1.14% | |
74 Outperform | $159.34B | 14.45 | 5.27% | 4.55% | 5.13% | -8.77% | |
72 Outperform | ¥28.30B | 11.24 | 2.05% | 15.27% | 48.08% | ||
70 Neutral | ¥175.70B | 11.17 | 6.37% | 3.52% | 3.93% | 6.03% |
Ishihara Chemical Co., Ltd. announced significant changes in its leadership structure, with new appointments in the roles of representative director and executive officers. These changes, set to be finalized at the upcoming Annual General Meeting, aim to adapt to the evolving management environment and enhance corporate value. The restructuring is expected to rejuvenate the management team, potentially impacting the company’s strategic direction and stakeholder relations.